Gardiquimod diTFA, an imidazoline analog and TLR7/8 agonist. Gardiquimod diTFA inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 at concentrations below 10 μM.

Physicochemical Properties

Molecular Formula	C21H25F6N5O5
Molecular Weight	541.44
Exact Mass	541.175
Elemental Analysis	C, 53.39; H, 5.66; F, 13.33; N, 16.39; O, 11.23
CAS #	1159840-61-5
Related CAS #	Gardiquimod;1020412-43-4
PubChem CID	44592365
Appearance	White to off-white solid powder
Hydrogen Bond Donor Count	5
Hydrogen Bond Acceptor Count	15
Rotatable Bond Count	5
Heavy Atom Count	37
Complexity	488
Defined Atom Stereocenter Count	0
SMILES	C(F)(F)(F)C(=O)O.C(N1C(=NC2C(N)=NC3=CC=CC=C3C1=2)CNCC)C(O)(C)C
InChi Key	XFQPQSJDMJVOBN-UHFFFAOYSA-N
InChi Code	InChI=1S/C17H23N5O.2C2HF3O2/c1-4-19-9-13-21-14-15(22(13)10-17(2,3)23)11-7-5-6-8-12(11)20-16(14)18;2*3-2(4,5)1(6)7/h5-8,19,23H,4,9-10H2,1-3H3,(H2,18,20);2*(H,6,7)
Chemical Name	1-(4-amino-2-((ethylamino)methyl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol 2,2,2-trifluoroacetate
Synonyms	Gardiquimod TFA salt;Gardiquimod trifluoroacetate
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	TLR7 TLR8 HIV-1
ln Vitro	Gardiquimod diTFA (6–60 μM) dramatically reduces HIV-1 reverse transcriptase's ability to synthesize cDNA[1].
ln Vivo	The anti-tumor actions of NK cells are enhanced when Dendritic cells (DCs) and Gardiquimod (1 mg/kg per mouse; ip; daily for 7 days) are combined[2].
Animal Protocol	Animal/Disease Models: Male athymic nude mice (Balb-nu/nu , 5 weeks old) (bearing human HepG2 liver carcinoma xenografts)[2] Doses: 1 mg/kg per mouse Route of Administration: ip; daily for 7 days Experimental Results: Dramatically suppressed the growth of human HepG2 liver carcinoma xenografts.
References	[1]. Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells. AIDS Res Hum Retroviruses. 2013 Jun;29(6):907-18. [2]. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice. Cell Mol Immunol. 2010 Sep;7(5):381-8. [3]. TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma. Cancer Lett. 2015 Dec 28;369(2):298-306.

Solubility Data

Solubility (In Vitro)

DMSO: ≥ 100 mg/mL Water:N/A Ethanol:N/A

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.5 mg/mL (4.62 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.62 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (4.62 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 4: 50 mg/mL (92.35 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	1.8469 mL	9.2346 mL	18.4693 mL
	5 mM	0.3694 mL	1.8469 mL	3.6939 mL
	10 mM	0.1847 mL	0.9235 mL	1.8469 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.